CXCL5 and early-onset autosomal dominant Alzheimer disease: CXCL5 has also been identified as a potential serum biomarker for white matter lesions in preterm infants, glial hyperplasia in Alzheimer’s disease and multiple sclerosis (MS) [21–23].